Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer

Chien Chung Lin, Wei Lun Huang, Fang Wei, Wu Chou Su, David T. Wong

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Advances in target therapies for lung cancer have enabled detection of gene mutations, specifically those of EGFR. Assays largely depend on the acquisition of tumor tissue biopsy, which is invasive and may not reflect the genomic profile of the tumor at treatment due to tumor heterogeneity or changes that occur during treatment through acquired resistance. Liquid biopsy, a blood test that detects evidence of cancer cells or tumor DNA, has generated considerable interest for its ability to detect EGFR mutations. However, its clinical application is limited by complicated collection methods and the need for technique-dependent platforms. Recently, simpler techniques for EGFR mutant detection in urine or saliva samples have been developed. This review focuses on advances in liquid biopsy and discusses its potential for clinical implementation in lung cancer.

Original languageEnglish
Pages (from-to)1427-1440
Number of pages14
JournalExpert Review of Molecular Diagnostics
Volume15
Issue number11
DOIs
Publication statusPublished - 2015 Nov 2

Fingerprint

Lung Neoplasms
Biopsy
Mutation
Neoplasms
Hematologic Tests
Saliva
Urine
DNA
Genes
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

@article{9bd6cc0e5241489aaf36516a61e10059,
title = "Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer",
abstract = "Advances in target therapies for lung cancer have enabled detection of gene mutations, specifically those of EGFR. Assays largely depend on the acquisition of tumor tissue biopsy, which is invasive and may not reflect the genomic profile of the tumor at treatment due to tumor heterogeneity or changes that occur during treatment through acquired resistance. Liquid biopsy, a blood test that detects evidence of cancer cells or tumor DNA, has generated considerable interest for its ability to detect EGFR mutations. However, its clinical application is limited by complicated collection methods and the need for technique-dependent platforms. Recently, simpler techniques for EGFR mutant detection in urine or saliva samples have been developed. This review focuses on advances in liquid biopsy and discusses its potential for clinical implementation in lung cancer.",
author = "Lin, {Chien Chung} and Huang, {Wei Lun} and Fang Wei and Su, {Wu Chou} and Wong, {David T.}",
year = "2015",
month = "11",
day = "2",
doi = "10.1586/14737159.2015.1094379",
language = "English",
volume = "15",
pages = "1427--1440",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "11",

}

Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer. / Lin, Chien Chung; Huang, Wei Lun; Wei, Fang; Su, Wu Chou; Wong, David T.

In: Expert Review of Molecular Diagnostics, Vol. 15, No. 11, 02.11.2015, p. 1427-1440.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer

AU - Lin, Chien Chung

AU - Huang, Wei Lun

AU - Wei, Fang

AU - Su, Wu Chou

AU - Wong, David T.

PY - 2015/11/2

Y1 - 2015/11/2

N2 - Advances in target therapies for lung cancer have enabled detection of gene mutations, specifically those of EGFR. Assays largely depend on the acquisition of tumor tissue biopsy, which is invasive and may not reflect the genomic profile of the tumor at treatment due to tumor heterogeneity or changes that occur during treatment through acquired resistance. Liquid biopsy, a blood test that detects evidence of cancer cells or tumor DNA, has generated considerable interest for its ability to detect EGFR mutations. However, its clinical application is limited by complicated collection methods and the need for technique-dependent platforms. Recently, simpler techniques for EGFR mutant detection in urine or saliva samples have been developed. This review focuses on advances in liquid biopsy and discusses its potential for clinical implementation in lung cancer.

AB - Advances in target therapies for lung cancer have enabled detection of gene mutations, specifically those of EGFR. Assays largely depend on the acquisition of tumor tissue biopsy, which is invasive and may not reflect the genomic profile of the tumor at treatment due to tumor heterogeneity or changes that occur during treatment through acquired resistance. Liquid biopsy, a blood test that detects evidence of cancer cells or tumor DNA, has generated considerable interest for its ability to detect EGFR mutations. However, its clinical application is limited by complicated collection methods and the need for technique-dependent platforms. Recently, simpler techniques for EGFR mutant detection in urine or saliva samples have been developed. This review focuses on advances in liquid biopsy and discusses its potential for clinical implementation in lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=84947125716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947125716&partnerID=8YFLogxK

U2 - 10.1586/14737159.2015.1094379

DO - 10.1586/14737159.2015.1094379

M3 - Review article

C2 - 26420338

AN - SCOPUS:84947125716

VL - 15

SP - 1427

EP - 1440

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 11

ER -